Skip to main content
GENFIT logo

GENFIT — Investor Relations & Filings

Ticker · GNFT ISIN · FR0004163111 LEI · 969500XPWN2DMZQA5X73 PA Professional, scientific and technical activities
Open in API
Filings indexed 681 across all filing types
Latest filing 2013-08-26 Regulatory Filings
Country FR France
Listing PA GNFT

About GENFIT

https://www.genfit.com

GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.

Recent filings

Filing Released Lang Actions
TGFTX1 Program: GENFIT discloses its technological accomplishments in a new scientific publication
Regulatory Filings Classification · 94% confidence The document is a press release dated August 26, 2013, announcing that GENFIT has published results detailing technological accomplishments regarding its TGFTX1 program (later named OLNORME). The text explicitly mentions a 'publication' in the Journal of Biomolecular Screening describing the approach and results. This is not a full financial report (like 10-K or IR), nor is it a standard earnings release (ER). It is an announcement about scientific progress and a related publication. Since it is a specific announcement about scientific/research progress and disclosure, it does not fit neatly into the standard financial filing categories (10-K, IR, ER, etc.). Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general, non-standard corporate announcement that isn't covered by the other specific codes, although 'LTR' (Legal Proceedings Report) or 'SR' (Environmental & Social Information) are clearly incorrect. However, since the core content is a scientific disclosure, and there is no specific code for 'Scientific Publication Announcement', RNS serves as the best general regulatory/corporate disclosure category available.
2013-08-26 English
Programme TGFTX1 : GENFIT révèle une avancée technologique dans une nouvelle publication scientifique
Regulatory Filings Classification · 97% confidence The document is a press release dated August 26, 2013, announcing a scientific breakthrough: the identification of a potent ROR receptor agonist through a novel screening approach involving plant extracts, published in 'The Journal of Biomolecular Screening'. This is a general announcement about scientific progress and partnership results, not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is a communication intended for the public and investors regarding research and development activities. Since it is a press release announcing scientific findings and collaborations, it best fits the general category for regulatory announcements or press releases that don't fit a more specific category like management changes (MANG) or dividend notices (DIV). Given the options, 'Regulatory Filings' (RNS) serves as the best general category for non-standard, yet important, corporate announcements that are not financial reports or specific corporate actions.
2013-08-26 French
GENFIT : CONVERSIONS EN ACTIONS DE 30 OBLIGATIONS OCA2012-2
Share Issue/Capital Change Classification · 99% confidence The document is a 'Communiqué de Presse Press Release' dated August 2, 2013, announcing the conversion of 30 convertible bonds (OCA2012-2) into new shares. This action directly impacts the company's capital structure (capital social and number of shares) and involves a financing/debt instrument (obligations/bonds). This falls under the category of updates on company fundraising, financing activities, or capital structure changes. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it pertains to a specific financing event.
2013-08-02 French
GENFIT: CONVERSIONS INTO SHARES OF 30 BONDS OCA2012-2
Capital/Financing Update Classification · 99% confidence The document explicitly announces the conversion of convertible bonds (OCA2012-2) into new shares, detailing the number of shares issued, the resulting increase in social capital, and the closure of the bond loan agreement. This action directly relates to changes in the company's capital structure and financing instruments. Based on the provided definitions, this falls under 'Capital/Financing Update' (CAP), as it details a specific financing event resulting in equity issuance.
2013-08-02 English
GENFIT : Conversions en actions de 20 obligations OCA2012-2
Capital/Financing Update Classification · 99% confidence The document is a press release dated July 17, 2013, announcing the conversion of convertible bonds (OCA2012-2) into new shares. This action directly impacts the company's capital structure (increase in share capital and total number of shares) due to a financing/debt instrument conversion. This falls under the category of updates on company fundraising, financing activities, or capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). It is not a general earnings release (ER) or a comprehensive interim report (IR), but a specific corporate action related to financing.
2013-07-17 French
GENFIT: Conversions into shares of 20 bonds OCA2012-2
Share Issue/Capital Change Classification · 99% confidence The document announces the conversion of convertible bonds (OCA2012-2) into new shares of GENFIT, resulting in an increase in the company's social capital and total number of shares. This action directly relates to changes in the company's capital structure and financing agreements. This fits the definition of 'Capital/Financing Update' (CAP), as it details the execution of a convertible loan agreement leading to share issuance. It is not a general earnings release (ER), a full annual report (10-K), or a simple dividend notice (DIV).
2013-07-17 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.